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much” to 4 “disagree/dissatisfied very much”. Correlation analysis was performed 
to identify the relationship between working motivation and job satisfaction. Also, 
multivariate regression analysis with stepwise method was conducted between 
overall job satisfaction and various working motivation dimensions. Results: 141 
out of 150 nurses filled out the questionnaire (RR 94%). The majority of the sample 
(68.8%) was female and belonged to the 21-30 years old group. Working motiva-
tion scoring was ranged from 2.54 to 2.04, meaning positive, except from work-
ing relationships (1.8 ±0.7). Also, the mean of overall job satisfaction was 2.3±0.6, 
meaning satisfied. Positive correlation was found between working motivation and 
job satisfaction (p≤ 0.01), with the exception of salary and working relationships. 
Personal development (β = 0.227), job interest (β = 0.254), responsibility (β = 0.149) and 
recognition (β = 0.154), were significant predictors of overall job satisfaction (p≤ 0.05). 
Reporting high motivation from work was positively and significantly associated 
with higher job satisfaction. ConClusions: Working motivation of health profes-
sionals contributes to the enhancement of their job satisfaction and consequently 
to the improvement of health services provision.
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objeCtives: To assess the job satisfaction of the nursing staff of the Pafos General 
Hospital in Cyprus. Methods: A cross-sectional survey was conducted in April 
2014. All 150 nurses (RR= 100%) working at the General Hospital of Pafos filled out a 
standardized, self-administered questionnaire with a 5-point Likert scale, regarding 
the assessment of job satisfaction, working conditions and personal well being. The 
questionnaire scoring from 1 represented “very dissatisfied” to 5 “very satisfied”. In 
order to investigate the association among job satisfaction as dependent variable 
and sociodemographic characteristics of the sample, satisfaction of working condi-
tions and personal well being as independent variables, multiple linear regression 
analysis was performed with backward method. Also, correlation analysis, using 
Spearman rank coefficient, was conducted to quantify the strength of association 
among job satisfaction and independent variables. Results: The majority of the 
sample (64.7%) was female and permanent employees (60.7%). The mean age was 
33.7 (S.D. 9.7) years. The personal well being score was 4.1 (S.D. 0.6), which means 
satisfied. The working conditions and job satisfaction scores were 2.2 (S.D. 0.7) and 
2.9 (S.D. 0.9), showing low and moderate satisfaction respectively. Age (β = -0.321, 
95% C.I. -0.650, -0.008), permanency of job (β = 0.346, 95% C.I. -0.005, 0.697), satisfac-
tion of working conditions (β = 0.532, 95% C.I. 0.331, 0.732) and personal well being 
(β = 0.444, 95% C.I. 0.188, 0.700) were significant predictors of overall satisfaction 
(p≤ 0.05). Positive correlation was found between job satisfaction and working con-
ditions (rs = 0.349, p ≤ 0.001) and personal well being (rs = 0.185, p ≤ 0.024) respec-
tively. ConClusions: The assessment of nurses’ working conditions appears to 
contribute to the improvement of job satisfaction, the enhancement of productivity 
and nursing care outcomes.
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legal and etHIcal ImPlIcatIons oF usIng data From socIal medIa 
WebsItes
Khankhel Z., Abogunrin S., Martin A.
Evidera, London, UK
objeCtives: Most social media (SM) sites have common terms and conditions dic-
tating how data from the sites may be used, but how these relate to health care 
research is usually unclear. We analyzed studies included in two separate system-
atic literature reviews to assess whether researchers have evaluated the legal and 
ethical implications of using SM as a clinical tool or as a data source for health 
care research. Methods: In the first review, MEDLINE and Embase were searched 
(2008-2013) for articles evaluating the use of SM as a tool or application in health 
care. In the second review, MEDLINE and Embase were searched for English lan-
guage studies on the use of SM in the context of adult vaccination. We assessed 
whether any of the individual studies considered the legal and ethical implications 
of using SM sources. Results: The first review identified 3,232 unique abstracts; 36 
reported on interactive, internet-delivered programs, Facebook, and mobile apps, for 
improving health outcomes of patients with cancer, or inflammatory, mental health, 
musculoskeletal, neurologic, ophthalmologic, or sexual health-related disorders. The 
second review identified 1,264 publications, of which 32 used SM to communicate 
with patients, analyze content, or recruit patients for studies related to perceptions 
of adult vaccines. Among these 68 publications, no study reported whether the legal 
or ethical implications of using SM content were considered prior to conducting 
research. ConClusions: The evidence suggests that legal and ethical implications 
of utilizing data from SM websites are not reported, and may not be considered, in 
current SM research. It is unclear whether this reflects the lack of clarity about what 
these restrictions mean for health care research, or whether researchers are not aware 
that such restrictions may exist. An informed debate to raise awareness of these 
issues and come to an understanding of the best way forward is urgently needed.
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PHenomenon oF InaPProPrIate drug manuFacturIng In cHIna - Past 
and Present
Wan W.Y.H.
GfK NOP, London, UK
objeCtives: It was an unspoken fact that Chinese manufacturers copying patent-
protected drugs inappropriately (e.g. aripiprazole (neurology), pemetrexed (oncol-
ogy), tiotropium bromide (respiratory)). The purpose of this study is to explore this 
phenomenon among the drugs currently included in the National Drug Lists (NDLs) 
and trends in the recent years. Methods: Reimbursed drugs from three therapeu-
tic areas (neurology, oncology and respiratory) were identified from the 2012 NDLs. 
The marketing years of the import (originator) drugs and local ‘branded’/generic 
drugs were found using the online Drug Future Chinese Marketed Drugs Database 
(accessed December 2013 to January 2014). Results: 260 drugs for neurological 
diseases, 106 drugs for oncology and 76 drugs for respiratory diseases were identi-
fied; 92, 42 and 26 drugs respectively had the marketing years of both import brands 
and local brands were available. 32 (~35%) neurological drugs, 13 (31%) oncology 
drugs and 11 (42%) respiratory drugs had local ‘branded’/generic versions available 
before the imported (originator) version. Most of these drugs in all three therapeutic 
areas were marketed between 2002 and 2003, whilst their imported (originator) 
versions were marketed 1-7 years later. Since 2009, no originator drug has been 
found marketed later that their local ‘branded’/generic versions. ConClusions: 
The low number of local ‘branded’/generic drugs marketed before the imported 
drugs in recent years suggests that the IP issue in China might have improved since 
the 2009 health reform. Current Results also suggest that respiratory medicine was 
most popular for inappropriate local manufacturing. It is yet to find out whether this 
observation was related to the costs of the originator drugs, the market demand, dif-
ficulties in copying new molecules due to their complexity, or high cost of manufac-
turing. These results may act as the basis to further explore future IP issues in China.
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objeCtives: Studies on the ecology of medical care have provided a framework for 
health care systems, medical education, and clinical research. Ten years ago, Fukui 
et al. reported the ecology of medical care in Japan. However, medicine and health 
care organization has changed since then. In the current study, we conducted an 
updated evaluation and compared it to results observed 10 years ago to understand 
health care seeking behaviors of people in Japan. Methods: A population weighted 
random sample from a nationally representative panel was used to estimate the 
number of health-related symptoms, self-care, and health care utilization per 1,000 
individuals based on a prospective health diary recorded for one month. Variations 
in terms of age and gender were also examined. Results: Based on 4,548 persons 
(3,787 adults and 797 children), on average per 1,000 persons, 794 (95% Confidence 
Interval (CI): 782 - 805) had at least one symptom, 447 (95% CI: 433 - 462) used over-
the-counter drugs (OTC), and 265 (95% CI: 252 – 278) visited a physician’s office, 206 
(95% CI: 194 – 218) a primary care physician, 4 (95% CI: 2 - 5) a hospital emergency 
department, and 117 (95% CI: 107 - 126) a professional provider of complementary 
or alternative medical (CAM) care. Children had more physician visits, and adult 
used more OTC and CAM. Females were more likely than males to have symptoms, 
to visit their physician and to use OTC and CAM. ConClusions: Compared with 
the data from 2003, health care seeking behaviors of people with symptoms in Japan 
are remarkably similar, with the exception of an observed increase in the use of 
CAM. Results of this study would be useful for further delineation of health care 
seeking behaviors of people in the context of a health care system unique to Japan.
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WHat Is tHe ProPortIon oF PatIents WHo return counter reFerral 
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objeCtives: Counter referral success rate is defined as number of patients received 
back at the original referring service with counter referral slips divided by the total 
number of patients referred and received at the referral hospital. Study objective 
was to determine the number of patients who returned counter referral slips to 
the original referral service for confirmation of arrival to the hospital. Methods: 
Quasi-experimental study was carried out in two sub-locations in Kenya where 
hundred community health workers were trained on community based referral 
and counter referral model and issued with referral tools. Each was assigned 25 
households, instructed to regularly visit them in order to identify sick persons 
counsel and refer them to link hospitals. One hundred villages comprising 2209 
households with a population of 11,000 people were covered where the counter 
referral model was implemented. Results: During the 12 months of implementa-
tion, a total of 322 patients were identified, counseled and referred to link hospitals 
of whom 93% (298/322) arrived the hospitals with referral and counter referral slips. 
The study showed that forty six percent (138/298) of counter referral slips had the 
name, signature and date of referring health worker, only 12% (35/298) indicated 
CHW’s telephone contact. Forty one percent (121/298) had the name and signature 
of attending physician of which 96% (116/121) had hospital stamp. Further, forty 
seven percent (140/298) of the patients returned counter referral slips to the original 
referral service for confirmation of arrival at the referral hospital. Fifty one percent 
(117/228) were satisfied with referral and counter referral process. ConClusions: 
It is concluded that referral and counter referral model is both feasible and accept-
able. However, referral protocols and other resources are necessary for the process 
to be successful. Further, both ends should be willing and prepared to receive those 
being referred there.
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WHat Is tHe PatIents’ medIan delay From tHe reFerrIng communIty 
HealtH Worker to arrIval In tHe lInk HealtH FacIlIty?
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objeCtives: Median delay could be defined as time taken in days from referring 
health facility to arrival at receiving link health facility. The purpose of the study 
was to determine the amount of time (in days) patients take to arrive at the link 
health facility for health care after being referred from the household by commu-
nity health workers. Methods: Quasi-experimental study was carried out in two 
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sub- locations in Kenya where hundred community health workers were trained 
on community based referral and counter referral model and issued with referral 
tools. Each was assigned 25 households, instructed to regularly visit them in order 
to identify sick persons counsel and refer them to link hospitals. One hundred vil-
lages comprising 2209 households with a population of 11,000 people were covered 
where the counter referral model was implemented. Results: Three hundred and 
twenty two sick persons were identified, counseled and referred to the two link 
health facilities by one hundred community health workers who covered one hun-
dred villages. It was further shown that 82% (263/322) arrived in the referral health 
facilities with referral slips on the same day, 5% (15/322) second day, 6% (20/322) 
third day and over while 7% (24/322) did not arrive in the hospitals. ConClusions: 
It was observed that community health workers regularly visited households. This 
observation is consistent with findings of previous similar studies. Only about less 
than a third of all the referrals did not arrive the link referral hospital the first day. 
It is therefore concluded that community health workers are a critical link between 
the households and primary health care facilities. They are likely to identify com-
mon illnesses during routine household visitation, counsel and refer sick persons 
to health facilities for care.
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cHoosIng ImPortant HealtH outcomes For comParatIve 
eFFectIveness researcH: a systematIc revIeW
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objeCtives: A core outcome set (COS) is a standardised set of outcomes which 
should be measured and reported, as a minimum, in all effectiveness trials for a 
specific health area. This will allow results to be compared, contrasted and com-
bined as appropriate, as well as ensuring that all trials contribute usable informa-
tion. The aim of this review was to identify studies which sought to determine 
which outcomes or domains to measure in all clinical trials in a specific condition, 
and to describe the methodological techniques used in these studies. Methods: 
We developed a multi-faceted search strategy for electronic databases (MEDLINE, 
SCOPUS, and Cochrane Methodology Register). We included studies which sought 
to determine which outcomes/domains to measure in all clinical trials in a specific 
condition. Results: 198 studies (250 reports) were included in the review. Studies 
covered various areas of health, most commonly cancer, rheumatology, neurology, 
heart and circulation, and dentistry and oral health. A variety of methods have been 
used to develop COS, including semi-structured discussion, unstructured group 
discussion, the Delphi Technique, Consensus Development Conference, surveys and 
Nominal Group Technique. The most common groups involved were clinical experts 
and non-clinical research experts. Thirty-one (16%) studies reported that the public 
had been involved in the process. The geographic locations of participants were pre-
dominantly North America (n= 164; 83%) and Europe (n= 150; 76%). ConClusions: 
This review has brought together the existing research in a single place. COS will 
increase the efficiency and value of the research process and make it easier for 
people to make well-informed decisions about health care. Design of new trials 
will be simplified, risk of measuring inappropriate outcomes reduced, and selec-
tive reporting of outcomes less likely. We have highlighted future areas of research, 
including the need for methodological guidance for COS development and better 
reporting of COS studies.
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objeCtives: Increasingly, patients are becoming more active contributors to 
research. The purpose of this survey was to understand the experience and expec-
tations of patient organizations (POs) with clinical research and patient reported 
outcomes. Methods: An online survey was conducted in English language during 
May 2014 among 40 participants of a global cross disease patient forum. The infor-
mation was used to provide background regarding patients as active contributors in 
clinical research. The participants represent a broad range of disease specific and 
general patient organizations from various countries including USA, European coun-
tries, Asia, Latina America, Middle East and Australia. Results: The most important 
deficiencies of current clinical research practice were described as a lack of patient 
friendly reporting, incomplete reporting and a lack of patient involvement in the 
study design. Over the half of respondents stated that clinical trials are conducted 
in a way that does not yield information relevant to the patients. Active involvement 
in clinical trials was specified through 79 different expectations which fell into 7 
categories: (1) Accessibility of new medicines (2) More representative patient selec-
tion for studies (3) Transparent conduct of the study (4) Better information on safety 
and risks to participants (5) Active versus passive role of patients (6) Contribution 
to innovation (7) Improved result reporting; especially to patients. One third of the 
respondents have already been actively involved in clinical research and felt that this 
was a mostly positive experience. Globally, patients and patient organizations are 
becoming increasingly involved in clinical research through multiple formal or infor-
mal routes of engagement. ConClusions: Patients should be better represented in 
clinical research and consulted for patient relevant study aspects in order to provide 
information of greater relevance to patients in their own therapeutic decisions.
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drug rePurPosIng as an eFFIcIent strategy In drug develoPment – 
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objeCtives: Traditionally, drug repurposing has been considered as a cost-effective 
and a reduced-risk strategy for developing new drugs. Currently little is known and 
documented regarding efficiency of repositioning strategies in drug development. 
The objective of this article is to assess the meaning of this process with focus on 
CNS area. We aim to identify the repositioning strategies that conducted to the 
discovery and development of new CNS products as well as identify the source and 
target indication and development status. Methods: In order to identify repur-
posing cases that target CNS, an extensive research was performed. It included a 
literature review as well as search of websites of organizations engaged in promot-
ing and development of drug repurposing. Cases were extracted from the source 
material. For each molecule, its initial and target indication as well as development 
status was recorded. Each case was classified by type of repurposing strategy (repo-
sitioning, reformulation or both). Results: 109 source products were identified. 
They were repositioned 183 times. About one third of the source products have 
been repositioned more than one time. Half of new indications was approved. The 
majority of cases were repositioned while only 10 were reformulated and 16 were 
reformulated and repositioned at the same time. The highest number of repurposed 
molecules was originating from CNS therapeutic area (67 molecules targeted 127 
indications). Among new therapeutic indications alcohol / opioid / drug dependence 
was targeted most often (20 repositions). Regarding repositions within CNS area, 
Schizophrenia, Epilepsy and Depression were the richest sources of repositioned 
drugs with 10 and more products each. ConClusions: Drug repurposing in CNS is 
an efficient and currently very active drug development strategy, exemplified by the 
considerable amount of new indications that have been found via this strategy, with 
approximately half of the target indications being currently under development.
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comPonents oF sustaInable HealtH systems: WHat Is knoWn about 
tHe cost-eFFectIveness oF clInIcal care?
Tordrup D., Stephan L., Bertollini R.
World Health Organization, Bruxelles, Belgium
objeCtives: Evidence to ensure cost-effective purchasing of services are an 
important pre-requisite for ensuring financial sustainability of health systems. 
The Research Agenda for Health Economic Evaluation project aims to map out the 
economic evidence available for the treatment of the 10 highest burden conditions 
in the European Union and identify evidence gaps. Methods:  The 10 highest 
burden diseases are selected by Disability Adjusted Life Years (DALYs) based on 
the Global Burden of Disease study for Europe (Ischemic Heart Disease, Low Back 
Pain, Stroke, Major Depressive Disorder, Lung Cancer, Falls, COPD, Diabetes, Other 
musculoskeletal, Neck pain). Clinical pathways are generated for these conditions by 
merging published clinical guidelines from public and professional bodies. Economic 
(cost-benefit and cost-effectiveness) evidence indexed by MEDLINE is stratified by 
treatment pathways to identify evidence gaps. Existing reviews are analysed to 
assess coverage of primary evidence. Results: Results are presented for diabetes: 
1,208 articles were retrieved from MEDLINE, of which 315 mapped to the treatment 
pathway. Most evidence was published after 2000. 74 reviews were identified, of 
which 24 were published between 2009-13. Volume of economic studies for each 
treatment ranged from 0 to 39 studies. The most intensively studied were diabetic 
retinopathy (n= 39), foot ulcers (n= 34) and renal disease (n= 31). Areas with no eco-
nomic evidence included non-pharmacological blood pressure and dyslipidemia 
control. In some cases economic evidence was available, but no recent reviews of 
the evidence were identified (eg. islet or pancreas transplantation, diabetic neu-
ropathy, interventions for weight loss). ConClusions: Economic evidence was 
available for the majority of treatment modalities for diabetes, however for several 
treatments no studies were identified. Importantly, reviews were not identified 
for several treatments where economic evidence was available. Lack of economic 
evidence prevents cost-effective commissioning, and lack of reviews of evidence 
may be a further barrier to translation.
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HealtH care reForm In cHIna and tHe unIted states: a tale oF tWo 
natIons seekIng to ImProve access to aFFordable coverage
Moore R.
Decision Resources Group, Nashville, TN, USA
objeCtives: China and the United States have approved massive health care 
reforms seeking to increase access to affordable health care services. Both coun-
tries employed a composite of government programs and private enterprises 
designed to improve efficiencies in their health care markets. This study com-
pares the results of these health care reforms so far, explores the longer-term 
prognoses and considers how lessons learnt can inform health care reform else-
where. Methods: In the U.S., 80 MCOs and 240 physicians were surveyed about 
their participation in reform programs. Quarterly data on the uninsured and health 
care cost trend data were also assessed. In China, 670 patients were surveyed 
regarding their access to a health care provider. Results: Early returns show 
mixed results that stem from policy decisions inherent in the original programs 
as well as from national political considerations. Overall, both the U.S. and China 
health care reforms are enjoying success but have shortcomings. In the U.S, parti-
sanship, technology issues, and implementation uncertainties have undermined 
the reform legislation. However, the nation’s uninsured rate declined from 17.1% 
in Q4 2013 to 13.4% in Q2 2014, and the health care cost trend has fallen. Moreover, 
the predicted spike in emergency room utilization has not yet appeared. In China, 
the percentage of citizens with coverage increased from 30% in 2003 to 95% in 2011, 
while patients’ share of out-of-pocket costs fell. However, improvement is felt less 
in rural regions and demand for services is increasing. Consequently, Chinese 
citizens still have difficulty accessing health care providers, which, combined 
with inadequate reimbursement rates, means health care in China remains sub-
optimal. ConClusions: Together with early coverage statistics, responses from 
both the U. S. and China to challenges in their respective health care reform efforts 
indicate that long-term success is achievable. Their experiences underscore the 
